Pseudomonas aeruginosa Exotoxin A

An NAD-dependent ADP-ribosyltransferase that catalyzes the transfer of the ADP ribosyl moiety of oxidized NAD onto elongation factor 2 (EF-2) thus arresting protein synthesis. Commonly used as the toxin in immunotoxins.

Also Known As:

ETA, Pseudomonas; PE38QQR; PE40 toxin; Exotoxin A, Pseudomonas; Exotoxin A, Pseudomonas aeruginosa; Recombinant Truncated Pseudomonas Exotoxin A, Form PE38QQR; Recombinant Truncated Pseudomonas Exotoxin A, Form PE40; ToxA protein, Pseudomonas aeruginosa

Networked: 61 relevant articles (3 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Puri, Raj K: 6 articles (01/2010 - 10/2003)
2.	Anniko, Matti: 3 articles (01/2006 - 01/2003)
3.	Palacio-Castañeda, Valentina: 2 articles (11/2021 - 05/2021)
4.	Fattom, Ali: 2 articles (01/2015 - 12/2004)
5.	Debinski, Waldemar: 2 articles (10/2013 - 05/2010)
6.	Husain, Syed R: 2 articles (04/2006 - 10/2003)
7.	Kawakami, Koji: 2 articles (09/2004 - 02/2004)
8.	Kawakami, Mariko: 2 articles (09/2004 - 02/2004)
9.	Maeta, Manabu: 2 articles (01/2003 - 01/2003)
10.	Puri, R K: 2 articles (05/2001 - 04/2001)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2007 - "Pseudomonas aeruginosa exotoxin A (ETA) is known to inhibit cell growth and trigger significant cell death in various cancer cells. " 04/20/1990 - "To be capable of selective killing of tumor cells, the non-selective Pseudomonas aeruginosa exotoxin A must have its cell-binding domain inactivated or removed and then be chemically linked to, or genetically fused with, a specific targeting agent. " 01/01/2023 - "New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery." 09/01/2010 - "Since recent advances in the understanding of bacterial toxins have produced new strategies for the treatment of cancers, we investigated the effect of Pseudomonas aeruginosa exotoxin A (PEA) on HSP70 expression and induction of apoptosis in chemoresistant OSCC cell line (YD-9). " 07/01/1990 - "A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A."
2.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/2015 - "In a previous study in end-stage renal disease (ESRD) hemodialysis patients, a single dose of Staphylococcus aureus type 5 and 8 capsular polysaccharides (T5/T8) conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A investigational vaccine showed no efficacy against S. "
3.	Fibrosis (Cirrhosis) 01/15/2010 - "Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A."
4.	Glioma (Gliomas) 09/01/2004 - "With IL-13R-targeted cytotoxin (IL13-PE38QQR, comprising IL-13 and a mutated form of Pseudomonas exotoxin [PE]) being tested in three Phase I/II clinical trials for the treatment of adult human glioma, and with pediatric studies being planned, the authors set out to analyze pediatric brain tumor tissue specimens for the expression of IL-13R. " 04/15/2006 - "Cintredekin besudotox (also known as IL13- PE38QQR) is a recombinant chimeric cytotoxin consisting of interleukin-13 and a truncated exotoxin produced by the Pseudomonas aeruginosa bacterium, which targets malignant glioma cells. "
5.	Brain Neoplasms (Brain Tumor) 01/01/2004 - "Intratumoral infusion of a recombinant targeted toxin (NBI-3001) consisting of the receptor binding domain of human interleukin 4 (IL-4) and Pseudomonas aeruginosa exotoxin A is an investigational treatment for malignant brain tumors. " 09/01/2004 - "With IL-13R-targeted cytotoxin (IL13-PE38QQR, comprising IL-13 and a mutated form of Pseudomonas exotoxin [PE]) being tested in three Phase I/II clinical trials for the treatment of adult human glioma, and with pediatric studies being planned, the authors set out to analyze pediatric brain tumor tissue specimens for the expression of IL-13R. "

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	Polysaccharides (Glycans)
4.	IL13-PE38
5.	Oncogene Proteins (Oncogene Protein)
6.	Interleukin-13
7.	Exotoxins
8.	Cytotoxins (Cytolysins)
9.	Immunotoxins (Immunotoxin)
10.	Designed Ankyrin Repeat Proteins

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics
3.	Immunotherapy
4.	Investigational Therapies (Experimental Therapy)